Navigation Links
FREEDOM-M Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Meets Primary Endpoint
Date:6/6/2011

ry infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.
  • TYVASO may increase the risk of bleeding, particularly in patients receiving anticoagulants.
  • In patients with low systemic arterial pressure, TYVASO may cause symptomatic hypotension.  The concomitant use of TYVASO with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.
  • Hepatic or renal insufficiency may increase exposure to TYVASO and decrease tolerability.  TYVASO dosage adjustments may be necessary if inhibitors of CYP2C8 such as gemfibrozil or inducers such as rifampin are added or withdrawn.
  • The most common adverse events seen with TYVASO in greater than or equal to 4% of PAH patients and more than 3% greater than placebo in the placebo-controlled clinical study were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs <1%), and syncope (6% vs <1%).
  • TYVASO should be used in pregnancy only if clearly needed.  Caution should be exercised when TYVASO is administered to nursing women.

    • For more information about TYVASO, please see the Full Prescribing Information, Patient Package Insert, and the TYVASO Inhalation System Instructions for Use manual at www.Tyvaso.com or call 877-UNITHER (877-864-8437).

    About Remodulin (treprostinil) Injection

    Indication

    Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective ti
    '/>"/>

    SOURCE United Therapeutics Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
    2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
    4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
    8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
    9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
    11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
    (Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
    (Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
    Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
    ... Reportlinker.com announces that a new market research report is available in its catalogue: , ... European Markets for Gastrointestinal Endoscopic Devices 2010 ... http://www.reportlinker.com/p0196554/European-Markets-for-Gastrointestinal-Endoscopic-Devices-2010-15-Countries.html ... The European market for gastrointestinal endoscopic devices was ...
    ... July 6 E. Fougera & Co., a leading ... from the FDA for Adapalene Cream 0.1% (Rx).  Fougera,s Adapalene ... Galderma Pharmaceuticals. According to industry data, U.S. sales of the ... This approval also marks the fourth product approval that the ...
    Cached Medicine Technology:Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 2Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 3Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 4Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 5Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 6Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 7Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 8Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 9Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 10Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 11Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 12Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 13Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 14Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 15Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 16Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 17Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 18Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 19Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 20Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 21Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 22Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 23Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 24Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 25Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 26Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 27Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 28Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 29Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 30Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 31Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 32Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries) 33Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 2Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin® 3
    (Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
    (Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
    (Date:5/25/2013)... May 25, 2013 On May 25, ... cancer research and advocacy, comments on a new study ... shows incorporating cold atmospheric plasma into brain cancer treatment ... According to a Science Daily article, physicists ... biologists and physicians demonstrated the “synergistic effect of cold ...
    (Date:5/25/2013)... 25, 2013 According to world-renowned scholars, ... and powerful women that ever lived. Cleopatra’s legendary beauty ... of the most powerful men in her time. Cleopatra ... to keep her skin glowing and fresh, from her ... wax, maringa oil and cyprus grass. , Cleopatra was ...
    (Date:5/25/2013)... Bradley, Illinois (PRWEB) May 25, 2013 ... assisted living community, is hosting an American Red Cross ... May 30. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... give the Gift of Life," says Andrea Arview Frey, ...
    Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
    ... SHANGHAI , Feb. 12 General Nutrition Centers, ... today that it, together with its parent company, has entered into ... Food (Group) Co., LTD (Bright Food). The partnership, to be named ... Bright Food , a leading state-owned conglomerate in China ...
    ... obesity and high-risk pregnancies caused by preeclampsia and diabetes ... Institutes of Health research grant received by Sean Blackwell, ... and Reproductive Sciences at The University of Texas Medical ... will provide them with a better understanding of the ...
    ... who received male donors, plasma had worse outcomes, study ... U.S. blood-banking industry discourages transfusing the blood product known ... dangerous reaction in the recipients. , But now researchers ... actually have advantages. , Plasma is the fluid ...
    ... Deaths totaled over 17,000, still fewer than ,typical, flu season ... swine flu pandemic apparently winding down, federal health officials said ... illness since last April, and the total could range as ... for Disease Control and Prevention (CDC) estimates that as many ...
    ... in humans, research shows , FRIDAY, Feb. 12 (HealthDay News) -- ... on the balls of your feet or on your toes, a ... 83 percent more energy to walk on your toes and 53 ... according to the University of Utah researchers. They measured energy expenditure ...
    ... others boosts attractiveness , FRIDAY, Feb. 12 (HealthDay News) ... with? New research suggests you,ll gain extra points ... others in activities like volunteering. , When it comes ... author Pat Barclay, an assistant professor at the University ...
    Cached Medicine News:Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:UT researcher receives $2.4 million to research obesity, high-risk pregnancy 2Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 3Health News:Heel-First Walking Conserves Energy 2Health News:Want to Find Love? Be Giving 2Health News:Want to Find Love? Be Giving 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: